ZYDUSWELLFast Moving Consumer Goods

Zydus Wellness Limited

Packaged Foods · ISIN INE768C01028 · BSE 531335 · NSE EQ · FV ₹2
Last price
₹546
-1.02%today
What this company does

Zydus Wellness Limited operates in Packaged Foods, part of the Fast Moving Consumer Goods sector. It booked ₹1,437 cr of revenue in its latest quarter (Q1 FY27) and kept 8.3% of sales as profit. It is the 4th largest of 9 Packaged Foods companies we track, by market value.

In the report:
56out of 100
Equitytale Health Score
Mixed

Healthier than 56% of companies in Fast Moving Consumer Goods, on all six measures of filed financials. Each measure is ranked against the 89–149 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
51

At close. Not part of the score.

Profitability & returns40

How much profit it earns on the money it employs

Balance sheet46

How much it owes, and whether earnings cover the interest

Cash quality73

Whether reported profit actually arrives as cash

Growth & consistency64

Whether sales and profit have grown, and how steadily

Valuation41

What today's price implies, against our models or its peers

Governance & risk100

How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure

Is this company doing well?
not investment advice
Strengths
Makes a profit
Sales up 67% vs last year
Promoters hold 70%
No promoter shares pledged
Turns profit into real cash
Watch-outs
! Profit down 7% vs last year

What if I invest in ZYDUSWELL?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 15% a year, it would become
₹26.30 lakh

The slider starts at 15%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest quarter + price
₹546 -1.02%
latest close · 2026-09-17
52-wk low ₹49042 sessions so far52-wk high ₹610
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio36.5High
LowAverageHigh
P/B ratio2.98Moderate
Below bookModerateHigh
EV / EBITDA20.8High
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity8.2%Fair
WeakFairStrong ▸15%
Return on capital7.9%Weak
WeakFairStrong
Net margin8.3%Decent
ThinDecentStrong
EBITDA margin17.1%Decent
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.55Moderate
LowModerateHigh ▸1
Interest cover7.2×Strong
RiskyOkayStrong ▸5×
Current ratio1.88Healthy
Tight ◂1HealthyAmple
More figures
Market cap
₹17,368 cr
Book value
₹183
EPS
₹3.74
latest quarter
Net debt
₹3,076 cr
owes more than its cash
Enterprise value
₹20,443 cr
EBITDA
₹982 cr
annualised
EBIT
₹754 cr
annualised
Operating margin
13.1%
Return on assets
4.6%
Earnings yield
2.74%
P/S
3.02
Sales / share
₹180.8
Tax rate
26.7%
Face value
₹2
Shares
31.8 cr
Working capital
₹638 cr
Current assets
₹1,367 cr
Current liabilities
₹729 cr
Delivery %
45.3%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.

Worth vs price · from the FY 2024 report & filings
not investment advice
Hard to value confidentlyLow confidence
The market price is far above what these earnings- and book-based models support — a fast-growing or asset-light business can trade well above them for years, so we won't put a confident number on how overpriced it is.
Models span ₹52₹61, midpoint ₹56

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · Q1 FY27 (consolidated)
Revenue from Operations₹1,437 cr
Other Income₹4 cr
Total Income₹1,441 cr
Cost of Materials₹308 cr
Purchases of Stock-in-Trade₹143 cr
Inventory Change (±)₹43 cr
Employee Benefit Expense₹97 cr
Finance Costs₹26 cr
Depreciation & Amortisation₹57 cr
Other Expenses₹605 cr
Total Expenses₹1,279 cr
Profit before Tax₹162 cr
Tax Expense₹43 cr
Net Profit₹119 cr
Net margin on total income8.3%
Where the money goes · Q1 FY27
% of total income
Materials + stock-in-trade₹493 cr34.2%
Employee benefit expense₹97 cr6.7%
Finance costs₹26 cr1.8%
Depreciation & amortisation₹57 cr4.0%
Other expenses₹605 cr42.0%
Tax expense₹43 cr3.0%
Profit for the period₹119 cr8.3%
Total income ₹1,441 cradds up to ₹100 ✓
Quarterly results · consolidated (₹ cr)
MetricQ3 FY26Q4 FY26Q1 FY27
Revenue965 cr1,485 cr1,437 cr
Total income966 cr1,486 cr1,441 cr
Expenses1,001 cr1,309 cr1,279 cr
Profit before tax-42 cr177 cr162 cr
Tax-2 cr15 cr43 cr
Net profit (owners' share)-40 cr162 cr119 cr
Net margin (owners' share, on revenue)-4.1%10.9%8.3%
EPS (₹)-1.255.093.74
YoY (latest quarter): total income +66.8% · net profit -7.0%
Balance sheet & cash flow · as of Mar 2026
Moderate debt
Total assets
₹10,308 cr
Shareholder equity
₹5,826 cr
parent shareholders
Total debt
₹3,186 cr
Cash
₹111 cr
Cash flow · H1 FY26
Operating
₹93 cr
Investing
₹-2,868 cr
Financing
₹2,801 cr
Peer comparison
Packaged Foods · by market value
CompanyPriceMarket capP/E
Nestle India Limited₹1,371₹2.64 L cr68.9
Britannia Industries Limited₹4,982₹1.20 L cr50.7
The Bombay Burmah Trading Corporation Limited₹1,399₹19,738 cr8.5
Zydus Wellness Limitedthis company₹546₹17,368 cr36.5
Bikaji Foods International Limited₹553₹13,857 cr57.6
Mrs. Bectors Food Specialities Limited₹221₹6,772 cr43.8
Gopal Snacks Limited₹252₹3,145 cr61.2
ADF Foods Limited₹268₹2,942 cr42.6
Prataap Snacks Limited₹1,100₹2,581 cr30.4
Same industry · latest reported numbers · not a recommendation.
Corporate actions
Dividend yield
0.22%
trailing 12 months
Dividend / share (TTM)
₹1.2
Last dividend
₹1.2
ex 17 Jul 2026
ActionDetailEx-date
Dividend₹1.2 / share17 Jul 2026
Stock splitStock Split From Rs.10/- to Rs.2/-18 Sep 2025
Dividend₹6 / share11 Jul 2025
Dividend₹5 / share19 Jul 2024
Dividend₹5 / share21 Jul 2023
Dividend₹5 / share14 Jul 2022
Who owns it · 2026-06-30
No pledge
Promoter
69.6%
FII / Foreign
3.3%
DII / Domestic
19.1%
Retail / others
7.9%
Promoter stake up 1.1% over the last 12 quarters.
Smart-money activity
Insider trades
BoughtPrashant Babubhai Patel · Promoter Group27,25019 Aug 26
BoughtRinesh Gajjar · Employees/Designated Employees1,500 · ₹6.0 L12 Mar 26
BoughtPunit Adhia · Employees/Designated Employees300 · ₹1.1 L6 Mar 26
Bulk / block deals
short · NSE1657 Sep 26
short · NSE343 Sep 26
short · NSE10026 Aug 26
Stake changes
BoughtPPFAS Mutual Fund through its Schemes→ 7.27% · 46.27 L17 Jun 25
SoldThrepsi Care LLP→ 0.00% · 46.27 L17 Jun 25
BoughtNippon Life India Trustee Limited→ 5.17% · 2.00 L5 Nov 24
What shareholders were asked to approve

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Yearly shareholder meeting · 30 Jul 2025
See the official result
1
Adoption of Standalone Audited Financial Statements for the financial year ended on March 31, 2025 and the Report of Board of Directors and Auditors thereon
Backed by 100% of shareholders other than promotersneeded 50%
1.39 cr votes for, 59 against · 0% of mutual funds and other big investors said no
2
Adoption of Consolidated Audited Financial Statements for the financial year ended on March 31, 2025 and the Report of Auditors thereon
Backed by 100% of shareholders other than promotersneeded 50%
1.39 cr votes for, 61 against · 0% of mutual funds and other big investors said no
3
Declaration of Dividend of Rs. 6/- per equity share of Rs. 10/- each for the financial year ended on March 31, 2025
Backed by 100% of shareholders other than promotersneeded 50%
1.40 cr votes for, 52 against · 0% of mutual funds and other big investors said no
4
Re-appointment of Mr. Ganesh Nayak, as a Non-Executive Director of the Company, liable to retire by rotation
Backed by 99% of shareholders other than promotersneeded 50%
1.39 cr votes for, 97,650 against · 1% of mutual funds and other big investors said no

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 129 named members
owning 69.6% between them · as of 2026-06-30
Zydus Lifesciences Limited57.59%
Zydus Family Trust(Trustee:Mr. Pankaj R. Patel,Smt. Pritiben P. Patel, Dr. Sharvil P. Patel)12.01%
Late Jasodaben Babubhai Patel0.01%
Aleta Hospitals LLPno shares
Alidac Healthcare (Myanmar) Limitedno shares
Alidac Pharmaceuticals SA (Pty) Ltdno shares
Alidac UK Limitedno shares
Alligator IP LLCno shares
Business done with them
FY2026 · 6 of the group
The company paid ₹71 cr to companies in the promoter group last year — about 1.8% of its ₹3,961 cr revenue and received ₹8 cr back from them.
ZYDUS HEALTHCARE LIMITED
Transfers Under Finance Agreements To Entity · Business Transactions
₹35 cr
company paid
ZYDUS LIFESCIENCES LIMITED
Other payments to them · Business Transactions
also owns 57.59% of the company
₹23 cr
company paid
ZYDUS HEALTHCARE LIMITED
Bought goods from them · Business Transactions
₹7 cr
company paid
ZYDUS HEALTHCARE LIMITED
Sold goods to them · Business Transactions
₹5 cr
company received
ZYDUS LIFESCIENCES LIMITED
Paid them for services · Business Transactions
also owns 57.59% of the company
₹3 cr
company paid
ZYDUS HEALTHCARE LIMITED
Paid them for services · Business Transactions
₹2 cr
company paid
ZYDUS HEALTHCARE LIMITED
Provided services to them · Business Transactions
₹2 cr
company received
Zydus Foundation
Other payments to them · Business Transactions
₹90 L
company paid
LM Manufacturing India Private Limited
Provided services to them · Business Transactions
₹50 L
company received
Zydus Medtech Private Limited
Provided services to them · Business Transactions
₹30 L
company received
LM Manufacturing India Private Limited
Other income from them · Business Transactions
₹10 L
company received
Zydus Worldwide DMCC
Paid them for services · Business Transactions
₹10 L
company paid
ZYDUS LIFESCIENCES LIMITED
Sold goods to them · Business Transactions
also owns 57.59% of the company
₹10 L
company received
ZYDUS HEALTHCARE LIMITED
Other income from them · Business Transactions
₹10 L
company received

The company also transacted with 4 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.